Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2005
12/14/2005EP1604645A1 Viscous compositions containing carbon dioxide
12/14/2005EP1603915A1 SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
12/14/2005EP1603914A1 Compounds having activity at 5ht2c receptor and uses thereof
12/14/2005EP1603912A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
12/14/2005EP1603911A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
12/14/2005EP1603910A1 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
12/14/2005EP1603901A1 Tetrahydropyran compounds as tachykinin antagonists
12/14/2005EP1603894A1 Pharmacologically active novel dauer pheromone compound for controlling aging and stress and method for isolating and characterizing the same
12/14/2005EP1603893A1 Ep4 receptor antagonists
12/14/2005EP1603877A1 NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS
12/14/2005EP1603595A1 Pharmaceutical composition for treatment of drug dependence
12/14/2005EP1603592A2 Therapeutical use of anti-myelin associated glycoprotein (mag) antibodies
12/14/2005EP1603577A1 Compounds for the treatment of pain
12/14/2005EP1603576A1 Use of adenosine receptor agonists in therapy
12/14/2005EP1603564A2 Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic neuropathological or psychogenic pain symptoms
12/14/2005EP1603548A2 Method and composition for treating neurodegenerative disorders
12/14/2005EP1603533A1 Opioid delivery system
12/14/2005EP1603532A1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
12/14/2005EP1440052B1 Benzamide derivatives as antagonists of orexin receptors
12/14/2005EP1427709B1 3-substituted-4-pyrimidone derivatives
12/14/2005EP1417189B1 Acylaminothiazole derivatives, their preparation and therapeutic use
12/14/2005EP1330428B1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride
12/14/2005EP1326858B1 Piperidine compounds as anti-allergic
12/14/2005EP1280904B1 Pain signaling molecules
12/14/2005EP1261583B1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/14/2005EP1242104B1 Process of obtaining thylakoids from plants, pure thylakoids and use thereof
12/14/2005EP1119562B1 2,3-dihydro-1h-isoindole derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
12/14/2005EP1112255B1 4,4-biarylpiperidine derivatives with opioid receptor activity
12/14/2005EP1082103B1 Spill resistant pharmaceutical compositions
12/14/2005EP1007714B1 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
12/14/2005EP1007666B1 Neurturin receptor
12/14/2005EP0920504B1 Class e voltage-gated calcium channel antagonist and methods
12/14/2005CN1708511A Genes whose expression is increased in response to stimulation by corticotropin-releasing hormone
12/14/2005CN1708493A Selected CGRP antagonists, method for production and use thereof as medicament
12/14/2005CN1708478A P-(sulfonyl)-aryl and heteroaryls amines
12/14/2005CN1708311A Remedy for fibromyalgia
12/14/2005CN1708304A Use of piperazine sulfonic acid derivatives as CCR1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
12/14/2005CN1708297A Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
12/14/2005CN1708295A Pharmaceutical solutions of modafinil compounds and use in preparation of medicine for treatment of diseases
12/14/2005CN1708293A S1p receptor agonist for treating demyelinate disease
12/14/2005CN1708291A Transdermal therapeutic system provided with improved long-term carrying comfort
12/14/2005CN1706426A Application of ampelopsis plant and its extract in preparing medicine and health article
12/14/2005CN1231589C Eukaryotic gene expression cassette and uses thereof
12/14/2005CN1231483C 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives
12/14/2005CN1231473C Substituted arylpyrazines
12/14/2005CN1231468C Chemical compounds
12/14/2005CN1231467C High affinity ligands for nociceptin receptor ORL-1
12/14/2005CN1231464C Novel 3-substituted urea derivatives and medicinal use thereof
12/14/2005CN1231461C Bicyclo [2.2.1] heptanes and related compounds
12/14/2005CN1231458C Novel aryloxy-alkyl-dialkylamines compound
12/14/2005CN1231457C Substituted cycloheptaene and its preparation process and use
12/14/2005CN1231439C Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand
12/14/2005CN1231249C Medicine for dispelling alcohol effect and making method thereof
12/14/2005CN1231236C Sobering-up toxin-eliminating tea and its prepn
12/14/2005CN1231233C hinese medicine for drug rehabilitation and its prepn
12/14/2005CN1231213C Sobering-up liver-protecting composition and preparation thereof
12/13/2005US6974840 Therapeutic agents
12/13/2005US6974837 Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
12/13/2005US6974825 piperidines or pyrroles with an amido- or sulfonamidophenylamino group; reductive amination of a piperidone with a substituted arylamine then further arylation; ligand for the delta opiod receptor; less side effects than current mu agonists; oral
12/13/2005US6974824 N-substituted-4-(m-hydroxyphenyl)piperidine derivated and esters thereof, used to bind a kappa opioid receptor; treating drug addiction
12/13/2005US6974823 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
12/13/2005US6974821 Methods for treating neuropsychiatric disorders
12/13/2005US6974819 Alzheimer's disease; Parkinson's disease; Pick's disease; bipolar disorders; schizophrenia; alopecia; anticancer agents
12/13/2005US6974818 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
12/13/2005US6974810 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
12/13/2005US6974809 Inhibitors of interleukin 1-β converting enzyme
12/13/2005US6974808 CRF receptor antagonists and methods relating thereto
12/13/2005US6974578 for relieving pain associated with muscle contractions and cholinergic controlled secretions including excessive sweating
12/13/2005CA2435729C New film coating
12/13/2005CA2147274C Transdermal therapeutic system for administering physostigmin through the skin, and method of producing the system
12/10/2005CA2507847A1 Prostaglandin reductase
12/10/2005CA2507738A1 Modulation of peroxisome proliferator-activated receptors
12/09/2005CA2470417A1 Use of cortiocosteriods alone or in conjunction with nutritional therapy to reduce stress in animals
12/08/2005WO2005116212A2 Treatment of neurodegenerative disease through intracranial delivery of sirna
12/08/2005WO2005116191A1 Method of culturing embryonic stem cells with the use of amniotic membrane-origin factor
12/08/2005WO2005116002A2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
12/08/2005WO2005115993A1 Quinazoline derivative
12/08/2005WO2005115990A1 Cinnamide compound
12/08/2005WO2005115987A1 Therapeutic compounds: pyridine n oxide scaffold
12/08/2005WO2005115978A1 Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide
12/08/2005WO2005115976A1 3-amino-2-phenylpyrrolidine derivatives
12/08/2005WO2005115548A2 Treating depressive disorders with carbonic anhydrase activators
12/08/2005WO2005115547A2 Myricitrin compounds for sleeping disorders
12/08/2005WO2005115453A2 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
12/08/2005WO2005115396A2 Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders
12/08/2005WO2005115367A2 Modulation of neurotransmitter activity in neurons
12/08/2005WO2005082860A8 Tetracyclines and their use as calpain inhibitors
12/08/2005WO2005074968A3 Medical use of basic peptides
12/08/2005WO2005054432A3 Gene transfer for regulating smooth muscle tone
12/08/2005WO2005005627A3 Applications of a new class of enzymes: sulfiredoxines.
12/08/2005WO2002066494A3 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
12/08/2005WO2002057256A9 Piperazinylcarbonylquinolines and -isoquinolines
12/08/2005US20050272955 Substituted cyclopentene compounds
12/08/2005US20050272936 Imidazolium cxcr3 inhibitors
12/08/2005US20050272931 Vanilloid receptor ligands and their use in treatments
12/08/2005US20050272822 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
12/08/2005US20050272809 Remedies
12/08/2005US20050272804 Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
12/08/2005US20050272803 Phosphodiesterase 4 inhibitors
12/08/2005US20050272789 Triazole-derived kinase inhibitors and uses thereof
1 ... 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 ... 1833